Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC

NCT02707588 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

133

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: Pembrolizumab
DRUG: Cetuximab
RADIATION: Radiotherapy

Sponsor

Groupe Oncologie Radiotherapie Tete et Cou